CN105194146A - Application of Dianxianning to preparation of medicine preventing and treating Alzheimer's disease - Google Patents
Application of Dianxianning to preparation of medicine preventing and treating Alzheimer's disease Download PDFInfo
- Publication number
- CN105194146A CN105194146A CN201510354410.0A CN201510354410A CN105194146A CN 105194146 A CN105194146 A CN 105194146A CN 201510354410 A CN201510354410 A CN 201510354410A CN 105194146 A CN105194146 A CN 105194146A
- Authority
- CN
- China
- Prior art keywords
- dianxianning
- medicine
- nematicide
- culture medium
- sheet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses novel application of Dianxianning, namely application of Dianxianning to preparation of medicine preventing and treating the Alzheimer's disease. Dianxianning is a Chinese patent drug for treating epilepsy. Animal experiment results show that Dianxianning has an obvious inhibiting effect in treating paralysis phenotypes of animal pathological models of the Alzheimer's disease, that is, Dianxianning has potential for preventing or treating the Alzheimer's disease. Due to the novel application of Dianxianning, the adaptation disease range of Dianxianning is enlarged; Dianxianning can be applied to preparation of the medicine for preventing and treating the Alzheimer's disease.
Description
Technical field
The present invention relates to the novelty teabag of epilepsy medicine (Dianxianning), be specifically related to the application of epilepsy medicine (Dianxianning) in preparation prevention or treatment Alzheimer disease drugs, belong to tcm field.
Background technology
Alzheimer (Alazheimer ' sdisease, AD) is a kind of based on the nervous system degenerative disease of Progressive symmetric erythrokeratodermia cognitive disorder and memory impairment.Feature is shown as clinically with dysmnesia, aphasia, apraxia, agnosia, the infringement of visual space technical ability, n-back test obstacle and the generalized dementia such as personality and behavior change.The drug main being used for the treatment of Alzheimer at present will be divided into two classes: acetylcholinesteraseinhibitors inhibitors (as galantamine) and N-methyl-D-aspartate receptor (nmda receptor) antagonist (as memantine), but said medicine is expensive, side effect remarkable (hallucination, misunderstanding, dizziness, headache and tired), and can only control but can not reverse conditions of patients.
Modern medicine has carried out years of researches to the pathogenesis of Alzheimer, but due to its cause of disease complexity, the pathogenesis of this disease is still indefinite so far.Comparatively the theory of main flow is amyloid-beta (A β) theory at present; the core of this theory is that the A β of abnormal deposition in brain in patients is by a series of cascade reactions such as radical reaction, Mitochondrial oxidative damage and inflammatory reactions; directly or indirect action in neuron and neurogliocyte; finally cause neuronal function abnormal or dead; cause cognitive impairment and amnesia, finally cause dementia.
It is Alzheimer one of major pathologic features the most that the cerebral cortex of patients with Alzheimer disease and Hippocampus occur that amyloid beta (A β) assembles the senile plaque (SP) formed, amyloid-beta can effectively weaken synaptic structure and function, is the important substance causing Alzheimer.Therefore amyloid beta has become generally acknowledged screening prevention or the target for the treatment of Alzheimer disease drugs.
The Alzheimer cause of disease is complicated and morbidity link is more, and current Western medicine carries out intervening for a certain particular pathologies link of Alzheimer and often occurs drug resistance and serious adverse reaction.And Chinese medicine has the function Characteristics of various active composition, Mutiple Targets, treatment by Chinese herbs Alzheimer is made to have obvious superiority.
Summary of the invention
The object of the present invention is to provide a kind of novelty teabag of epilepsy medicine (Dianxianning), be specifically related to the application of epilepsy medicine (Dianxianning) in preparation prevention or treatment Alzheimer disease drugs.
Described epilepsy medicine (Dianxianning) dosage form can be tablet, pill, capsule, oral liquid or granule.Dosage form difference does not affect the function of epilepsy medicine (Dianxianning) in prevention or treatment Alzheimer.
The application of described epilepsy medicine (Dianxianning) disclosed by the invention in preparation prevention or treatment Alzheimer disease drugs, described epilepsy medicine (Dianxianning) is epilepsy medicine (Dianxianning) sheet.
Epilepsy medicine (Dianxianning) tablet is the Chinese patent medicine refined through modern pharmaceutical technique by Rhizoma valerianae latifoliae, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis, Semen Pharbitidis, Semen Euphorbiae, Rhizoma et radix valerianae, Radix Et Rhizoma Nardostachyos, Mentholum eight taste medicine.At present, epilepsy medicine (Dianxianning) disturbs epileptics on wind-phlegm, or for hysteria, insomnia etc.
Transgenic C nematicide strain CL4176 is evaluated epilepsy medicine (Dianxianning) prevention as the pathological model of screening prevention or treatment Alzheimer disease drugs or treats the effect of Alzheimer by the present invention, be based on: the cerebral cortex of patients with Alzheimer disease and Hippocampus occur amyloid beta (A β) assemble formed senile plaque (SP) be Alzheimer one of major pathologic features the most, amyloid-beta can effectively weaken synaptic structure and function, is the important substance causing Alzheimer.Transgenic C nematicide strain CL4176 expresses mankind A β at 25 DEG C of temperature-induced lower muscle specifics, and A β assembles in muscular tissue, finally causes nematicide to be benumbed.By drug effect in nematicide strain CL4176, if nematode population paralysis situation improves, be embodied in the remarkable retardation of paralysis time of nematicide, then illustrate that medicine has prevention or the effect for the treatment of Alzheimer.
Environmental change reaction is responsive to external world for Caenorhabditis elegans, and utilize C. Elegans Automatic Screening can carry out accurate evaluation to the toxicity of medicine, body length is one of assessing developmental toxicity index commonly used the most.Drug effect, after nematicide, significantly reduces if nematicide body is long, then illustrate that medicine has significant development toxicity to nematicide.
Compared with prior art, the present invention has following beneficial effect:
The present invention assesses the effect of epilepsy medicine (Dianxianning) to Caenorhabditis elegans Alzheimer disease model paralysis phenotype, result confirms that epilepsy medicine (Dianxianning) has obvious inhibitory action to Caenorhabditis elegans Alzheimer disease model paralysis phenotype, has the potentiality of prevention or treatment Alzheimer.
Therefore, Chinese patent medicine epilepsy medicine (Dianxianning) can be used for the medicine preparing prevention or treatment Alzheimer.
Accompanying drawing explanation
Below in conjunction with accompanying drawing, the specific embodiment of the present invention is described in further detail.
Fig. 1 is the impact of positive drug memantine on Caenorhabditis elegans Alzheimer disease model paralysis phenotype.
Fig. 2 is the impact of epilepsy medicine (Dianxianning) sheet on Caenorhabditis elegans Alzheimer disease model paralysis phenotype.
Fig. 3 is the evaluating drug effect experimental result of Rhizoma valerianae latifoliae, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis and epilepsy medicine (Dianxianning) sheet thereof.
Fig. 4 is the toxicity assessment experimental result of Rhizoma valerianae latifoliae and epilepsy medicine (Dianxianning) sheet.
Detailed description of the invention
Below provide specific embodiment to realize the application of epilepsy medicine (Dianxianning) of the present invention in preparation prevention or treatment Alzheimer disease drugs, but be not limited to these embodiments.
Embodiment one memantine is to the effect of Caenorhabditis elegans CL4176
1. biomaterial
(1) Caenorhabditis elegans CL4176 is purchased from CaenorhabditisGeneticsCenter; For transgenic strain, mankind A β is expressed at 25 DEG C of temperature-induced lower muscle specifics, A β assembles in muscular tissue, finally causes nematicide to be benumbed, and the present embodiment adopts C. Elegans Automatic Screening strain CL4176 as screening prevention or the pathological model for the treatment of Alzheimer disease drugs.
(2) escherichia coli OP50 (uracil leaky mutant), purchased from CaenorhabditisGeneticsCenter, as the food of Caenorhabditis elegans.
2. reagent
(1) memantine (MEM), chemical name: MEM amine hydrochlorate, molecular formula: C
12h
21nHCl, purchased from lark prestige science and technology, CAS:41100-52-1; Memantine is uncompetitive nmda receptor antagonist, be used for the treatment of middle severe to severe dementia of the Alzheimer type, bibliographical information memantine (2.16mg/ml) can significantly suppress transgenic nematode strain CL4176 to benumb phenotype, and the present embodiment it can be used as positive drug.
(2) solid NGM (NematodeGrowthMedium) medium component and making (being upgraded to example with 1):
| Composition | Content |
| NaCl | 3.00g |
| K 2HPO 4 | 2.34g |
| KH 2PO 4 | 17.23g |
| Peptone | 2.50g |
| Agar | 17.00g |
| Supplement H 2O extremely | 1000ml |
After solid NGM culture medium prepares, high-pressure constant temp sterilizing 20min at 121 DEG C, adds 5mg/ml cholesterol 1ml, 1MMgSO under aseptic operating platform
41ml, 1MCaCl
21ml, shakes up, and pours sterilized 9cm culture plate while hot into, about 20ml/ plate.Leave standstill and wait for culture medium solidifying, for subsequent use.
(3) the NGM culture medium of hydrochloric memantine is prepared
Memantine is dissolved in sterilized water, and preparation becomes the mother solution of 2.16mg/ml; Memantine mother solution is added in the NGM culture medium of thawing, is formulated as the NGM culture medium that hydrochloric memantine final concentration is 215.76 μ g/ml, 107.88 μ g/ml, 21.58 μ g/ml, 4.32 μ g/ml, 0.86 μ g/ml.
Blank is add the NGM culture medium with memantine equal-volume sterilized water under similarity condition.
Above-mentioned culture medium is all coated with the food of escherichia coli OP50 as nematicide.
(4) M9 formula of liquid
(5) preparation of lysate: 6.4%NaClO
3the 1:1 mixing by volume of solution and 1MNaOH solution.
3. implementation step
(1) cultivation of nematicide:
Be connected on by nematicide and scribble on the solid NGM plate of escherichia coli OP50, the incubator being then placed in 16 DEG C is cultivated, and carries out synchronization process when nematicide grows to adult.
(2) nematicide synchronization:
Select containing a large amount of adult and the NGM culture medium having partial line worm's ovum to hatch, with M9 liquid, nematicide is swept away from culture medium, transfer in centrifuge tube, leave standstill and make, at the bottom of nematicide free settling to pipe, to abandon supernatant.How many sight line worm amounts adds nematicide alkaline lysis liquid in centrifuge tube, whirlpool misfortune agitator vibrates 5-7 minute until nematicide complete rupture time stop vortex, and be sub-packed in 1.5mL centrifuge tube, wash line eggs three times with M9 solution.
(3) memantine (MEM) is to the effect of Caenorhabditis elegans CL4176
Transferred to by line eggs after nematicide synchronization and be coated with OP50 and mix in the NGM culture medium of variable concentrations memantine, blank is be coated with OP50 and be added with the NGM culture medium with memantine equal-volume sterilized water.Each culture medium 60 nematicides, each drug level, using three culture medium as parallel, cultivates 3 days to the L3 phase for 16 DEG C.
In order to make nematicide express A β, inducing at L3 phase nematicide is gone to 25 DEG C, starting after 34h to count nematicide paralysis number.Every two hours count once, until all nematicides are all benumbed (when paralysis refers to mechanical stimulus nematode body, nematicide can not move or only have head movement), the results are shown in Figure 1.
As seen from Figure 1, water-soluble positive drug memantine can significantly suppress CL4176 to benumb phenotype, 215.76 μ g/ml and 107.88 μ g/ml memantine strong inhibition elegans developments when 21.58 μ g/ml, 4.32 μ g/ml, 0.86 μ g/ml.Experimental result shows that this experimental system is normal, illustrates that the present invention can adopt C. Elegans Automatic Screening strain CL4176 as screening prevention or treatment Alzheimer disease drugs.
Embodiment two epilepsy medicine (Dianxianning) sheet is to the effect of Caenorhabditis elegans CL4176
1. biomaterial is with embodiment one.
2. reagent
(1) epilepsy medicine (Dianxianning) sheet: manufacturer: the Kunming pharmaceutical factory of traditional Chinese medicine, authentication code: the accurate word Z53020771 of traditional Chinese medicines.
(2) solid NGM (NematodeGrowthMedium) medium component and making (being upgraded to example with 1): with embodiment one.
(3) preparation is containing water-soluble epilepsy medicine (Dianxianning) sheet NGM culture medium
Flame heating epilepsy medicine (Dianxianning) sheet, uncoating.By epilepsy medicine (Dianxianning) sheet mortar pulverize, be dissolved in sterilized water, and be configured as 150mg/ml epilepsy medicine (Dianxianning) sheet aqueous solution, ultrasonic 30min under room temperature, and under 10000rpm centrifugal 10min, get supernatant, in 4 DEG C of preservations.Add in the NGM culture medium of thawing by epilepsy medicine (Dianxianning) sheet aqueous solution, it is the NGM culture medium of 1.0mg/ml, 5.0mg/ml, 15.0mg/ml that preparation becomes containing epilepsy medicine (Dianxianning) sheet final concentration.
Blank is add the NGM culture medium with epilepsy medicine (Dianxianning) sheet aqueous solution equal-volume sterilized water under similarity condition.
Above-mentioned culture medium is all coated with the food of escherichia coli OP50 as nematicide.
(4) M9 formula of liquid: with embodiment one.
(5) preparation of lysate: with embodiment one.
3. implementation step
(1) cultivation of nematicide: with embodiment one.
(2) nematicide synchronization: with embodiment one.
(3) epilepsy medicine (Dianxianning) sheet is to the effect of Caenorhabditis elegans CL4176
After nematicide synchronization, line eggs is transferred to and be coated with OP50 and mix in the NGM culture medium of epilepsy medicine (Dianxianning) sheet aqueous solution of variable concentrations, blank is be coated with OP50 and be added with the NGM culture medium with epilepsy medicine (Dianxianning) sheet aqueous solution equal-volume sterilized water, each culture medium 60 nematicides, each drug level three culture medium, as parallel, cultivate 3 days to the L3 phase for 16 DEG C.
In order to make nematicide express A β, L3 phase nematicide being turned and induces at 25 DEG C, start after 34h to count nematicide paralysis number.Every two hours count once, until all nematicides are all benumbed (when paralysis refers to mechanical stimulus nematode body, nematicide can not move or only have head movement), the results are shown in Figure 2.
As can be seen from experimental result, the paralysis that water-soluble epilepsy medicine (Dianxianning) sheet can significantly suppress transgenic C nematicide A β overexpression to cause at 15mg/ml, 5mg/ml, especially the nematicide that 15mg/ml epilepsy medicine (Dianxianning) sheet suppresses A β to cause very significantly benumbs phenotype (p < 0.001), and above-mentioned each group all presents certain dose-effect relationship.
In a word, as can be seen from the above-described embodiment, epilepsy medicine (Dianxianning) has obvious inhibitory action to the paralysis phenotype that Alzheimer animal pathological model Caenorhabditis elegans A beta peptide aggregation causes, and illustrates that epilepsy medicine (Dianxianning) has the potentiality of prevention or treatment Alzheimer.Novelty teabag of the present invention expands the indication of epilepsy medicine (Dianxianning), can apply in preparation prevention or treatment Alzheimer disease drugs.
The drug effect of embodiment three epilepsy medicine (Dianxianning) sheet and toxicity comparative evaluation experiment
1. biomaterial is with embodiment one.
2. reagent
(1) epilepsy medicine (Dianxianning) sheet: the Kunming pharmaceutical factory of traditional Chinese medicine (manufacturer), authentication code: the accurate word Z53020771 of traditional Chinese medicines.
(2) Rhizoma valerianae latifoliae, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis are purchased from the Lanzhou chain Co., Ltd of Hui Rentang Pharmaceutical.
(3) solid NGM (NematodeGrowthMedium) medium component and making (being upgraded to example with 1): with embodiment one.
(4) preparation is containing the NGM culture medium of epilepsy medicine (Dianxianning) sheet
Flame heating epilepsy medicine (Dianxianning) sheet, uncoating.By epilepsy medicine (Dianxianning) sheet mortar pulverize, be dissolved in sterilized water, and be configured as 150mg/ml epilepsy medicine (Dianxianning) sheet aqueous solution, ultrasonic 30min under room temperature, and under 10000rpm centrifugal 10min, get supernatant, in 4 DEG C of preservations.Add in the NGM culture medium of thawing by epilepsy medicine (Dianxianning) sheet aqueous solution, it is the NGM culture medium of 15.0mg/ml that preparation becomes containing epilepsy medicine (Dianxianning) sheet final concentration.
(5) prepare Rhizoma valerianae latifoliae extract and contain Rhizoma valerianae latifoliae extract NGM culture medium
3/5 weight portion of Rhizoma valerianae latifoliae gross weight extracts volatile oil, and medical material residue decocts with water 1-2 time, is preferably 2 times; Each 1-2 hour, is preferably 1.5 hours, and filter, merging filtrate, is evaporated to the extractum that relative density is 1.26-1.30, and preferred relative density is the extractum of 1.28; 2/5 parts by weight of crushed of Rhizoma valerianae latifoliae gross weight becomes fine powder for subsequent use.By above volatile oil, extractum and fine powder mix, add sterilized water dissolve, be configured to Rhizoma valerianae latifoliae aqueous solution, ultrasonic 30min under room temperature, and under 10000rpm centrifugal 10min, get supernatant, in 4 DEG C of preservations.Rhizoma valerianae latifoliae aqueous solution is added in the NGM culture medium of thawing, makes the Rhizoma valerianae latifoliae concentration in culture medium consistent with containing the Rhizoma valerianae latifoliae concentration in the NGM culture medium of epilepsy medicine (Dianxianning) sheet.
(6) prepare Rhizoma Acori Graminei extract and contain Rhizoma Acori Graminei extract NGM culture medium
Rhizoma Acori Gramineii extract volatile oil, medical material residue decocts with water 1-2 time, is preferably 2 times; Each 1-2 hour, is preferably 1.5 hours, filters, merging filtrate; Be evaporated to the extractum that relative density is 1.26-1.30, preferred relative density is the extractum of 1.28.By above volatile oil and extractum mixing, add sterilized water dissolve, be configured to Rhizoma Acori Graminei aqueous solution, ultrasonic 30min under room temperature, and under 10000rpm centrifugal 10min, get supernatant, in 4 DEG C of preservations.Rhizoma Acori Graminei aqueous solution is added in the NGM culture medium of thawing, makes the Rhizoma Acori Graminei concentration in culture medium consistent with containing the Rhizoma Acori Graminei concentration in the NGM culture medium of epilepsy medicine (Dianxianning) sheet.
(7) prepare Ramulus Uncariae Cum Uncis extract and contain Ramulus Uncariae Cum Uncis extract NGM culture medium
Ramulus Uncariae Cum Uncis decocts with water 1-2 time, is preferably 2 times; Each 1-2 hour, is preferably 1.5 hours, filters, merging filtrate; Be evaporated to the extractum that relative density is 1.26-1.30, preferred relative density is the extractum of 1.28.Add in extractum sterilized water dissolve, be configured to Ramulus Uncariae Cum Uncis aqueous solution, ultrasonic 30min under room temperature, and under 10000rpm centrifugal 10min, get supernatant, in 4 DEG C of preservations.Ramulus Uncariae Cum Uncis aqueous solution is added in the NGM culture medium of thawing, makes the Ramulus Uncariae Cum Uncis concentration in culture medium consistent with containing the Ramulus Uncariae Cum Uncis concentration in the NGM culture medium of epilepsy medicine (Dianxianning) sheet.
(8) prepare Rhizoma valerianae latifoliae, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis prescription extract and contain prescription NGM culture medium
3/5 weight portion and the Rhizoma Acori Graminei of getting Rhizoma valerianae latifoliae gross weight in formula 2 extract volatile oil respectively, merge, decoct with water residue obtained 1-2 time with Ramulus Uncariae Cum Uncis, are preferably 2 times; Each 1-2 hour, is preferably 1.5 hours, filters, merging filtrate; Be evaporated to the extractum that relative density is 1.26-1.30, preferred relative density is the extractum of 1.28.2/5 parts by weight of crushed of Rhizoma valerianae latifoliae gross weight becomes fine powder for subsequent use.By above volatile oil, extractum and fine powder mix, add sterilized water dissolve, be formulated as the aqueous solution of Rhizoma valerianae latifoliae, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis prescription extract, ultrasonic 30min under room temperature, and under 10000rpm centrifugal 10min, get supernatant, in 4 DEG C of preservations.The aqueous solution of Rhizoma valerianae latifoliae, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis prescription extract is added in the NGM culture medium of thawing, makes the Rhizoma valerianae latifoliae in culture medium, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis concentration consistent with the concentration containing the Rhizoma valerianae latifoliae in epilepsy medicine (Dianxianning) sheet NGM culture medium, Rhizoma Acori Graminei, Ramulus Uncariae Cum Uncis.
Blank is add the NGM culture medium with epilepsy medicine (Dianxianning) sheet aqueous solution equal-volume sterilized water under similarity condition.
Above-mentioned culture medium is all coated with the food of escherichia coli OP50 as nematicide.
(9) M9 formula of liquid: with embodiment one.
(10) preparation of lysate: with embodiment one.
3. implementation step
(1) cultivation of nematicide: with embodiment one.
(2) nematicide synchronization: with embodiment one.
(3) to the drug effect comparative evaluation of epilepsy medicine (Dianxianning) sheet
After nematicide synchronization, line eggs is transferred to and be coated with OP50 and the NGM culture medium, the NGM culture medium of Rhizoma valerianae latifoliae extract, the NGM culture medium of Rhizoma Acori Graminei extract, the NGM culture medium of Ramulus Uncariae Cum Uncis extract that mix epilepsy medicine (Dianxianning) sheet; Blank is be coated with OP50 and be added with the NGM culture medium with epilepsy medicine (Dianxianning) sheet aqueous solution equal-volume sterilized water, each culture dish 60 nematicides, cultivates 3 days to the L3 phase for 16 DEG C.
In order to make nematicide express A β, L3 phase nematicide being turned and induces at 25 DEG C, start after 34h to count nematicide paralysis number.Every two hours count once, until all nematicides are all benumbed (when paralysis refers to mechanical stimulus nematode body, nematicide can not move or only have head movement), the results are shown in Figure 3.
As can be seen from experimental result, nematicide paralysis phenotype (p < 0.001) that Rhizoma valerianae latifoliae, Ramulus Uncariae Cum Uncis and Rhizoma Acori Graminei all can significantly suppress A β to cause, wherein, it is best, almost suitable with epilepsy medicine (Dianxianning) sheet effect that the nematicide that Rhizoma valerianae latifoliae suppresses A β to cause benumbs phenotypic effect; Ramulus Uncariae Cum Uncis and Rhizoma Acori Graminei benumb phenotype inhibition not as good as epilepsy medicine (Dianxianning) sheet (P < 0.001) to nematicide.
(4) to the toxicity comparative evaluation of epilepsy medicine (Dianxianning) sheet
Immediately nematicide is placed in 50 DEG C of process 15min after paralysis experiment terminates, stretches to make nematode body and be convenient to measure.Examine under a microscope and use MvImage image processing system to take pictures and slotted line polypide length.The results are shown in Figure 4.
As can be seen from experimental result, compared with blank and epilepsy medicine (Dianxianning) sheet thereof, Rhizoma valerianae latifoliae group nematicide body is long significantly to be reduced, and show that Rhizoma valerianae latifoliae has inhibitory action significantly to nematode growth growth, toxicity is large compared with epilepsy medicine (Dianxianning) sheet.
The nematicide paralysis phenotype that Rhizoma valerianae latifoliae, Ramulus Uncariae Cum Uncis and Rhizoma Acori Graminei and epilepsy medicine (Dianxianning) sheet thereof all can significantly suppress A beta peptide aggregation to cause, wherein Rhizoma valerianae latifoliae and epilepsy medicine (Dianxianning) sheet effect optimum; Tested as can be seen from the toxicity assessment of the present embodiment, compared with blank and epilepsy medicine (Dianxianning) sheet thereof, Rhizoma valerianae latifoliae significantly suppresses nematode growth to be grown, and toxicity is significantly higher than epilepsy medicine (Dianxianning) sheet, and epilepsy medicine (Dianxianning) sheet does not almost affect nematicide body is long, show that epilepsy medicine (Dianxianning) sheet toxicity is significantly lower than Rhizoma valerianae latifoliae.
In a word, the present embodiment result shows that epilepsy medicine (Dianxianning) has Be very effective, feature that toxicity is little in prevention or treatment Alzheimer, illustrate that epilepsy medicine (Dianxianning) has the potentiality of prevention or treatment Alzheimer, novelty teabag of the present invention expands the indication of epilepsy medicine (Dianxianning), can apply in preparation prevention or treatment Alzheimer disease drugs.
Claims (3)
1. the application of epilepsy medicine (Dianxianning) in preparation prevention or treatment Alzheimer disease drugs.
2. the application of epilepsy medicine (Dianxianning) according to claim 1 in preparation prevention or treatment Alzheimer disease drugs, is characterized in that described epilepsy medicine (Dianxianning) is tablet, pill, capsule, oral liquid or granule.
3. the application of epilepsy medicine (Dianxianning) according to claim 2 in preparation prevention or treatment Alzheimer disease drugs, is characterized in that described epilepsy medicine (Dianxianning) is epilepsy medicine (Dianxianning) sheet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510354410.0A CN105194146B (en) | 2014-06-26 | 2015-06-25 | Application of the epilepsy medicine (Dianxianning) in prevention or treatment Alzheimer disease drugs is prepared |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/080789 | 2014-06-26 | ||
| PCT/CN2014/080789 WO2015196401A1 (en) | 2014-06-26 | 2014-06-26 | Use of α-asarone in preparing drugs for preventing and treating alzheimer's disease |
| CN201510354410.0A CN105194146B (en) | 2014-06-26 | 2015-06-25 | Application of the epilepsy medicine (Dianxianning) in prevention or treatment Alzheimer disease drugs is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105194146A true CN105194146A (en) | 2015-12-30 |
| CN105194146B CN105194146B (en) | 2018-02-09 |
Family
ID=54942331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510354410.0A Active CN105194146B (en) | 2014-06-26 | 2015-06-25 | Application of the epilepsy medicine (Dianxianning) in prevention or treatment Alzheimer disease drugs is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105194146B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816701A (en) * | 2016-03-30 | 2016-08-03 | 聂靖炜 | Brain-nourishing and refreshing capsules for treating epilepsy and dementia |
| CN107519323A (en) * | 2017-04-25 | 2017-12-29 | 兰州大学 | Rhizoma valerianae latifoliae extract is preparing the application in activating HSP70 medicines |
| CN109223924A (en) * | 2018-11-10 | 2019-01-18 | 兰州大学 | Epilepsy medicine (Dianxianning) adjusts the application in beta-amyloid protein drug in preparation |
| CN109512813A (en) * | 2018-07-24 | 2019-03-26 | 宁夏医科大学 | Purposes of the valeric aldehyde in preparation prevention and treatment epileptic attack and cerebral injury drug |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1084756A (en) * | 1993-04-19 | 1994-04-06 | 高为人 | Epilepsy medicine (Dianxianning) and manufacture method thereof |
| CN1134298A (en) * | 1996-01-05 | 1996-10-30 | 谢志庆 | "Dianxianningxiwan" pills-Chinese patent medicine for epilepsy |
| CN101732515A (en) * | 2010-01-26 | 2010-06-16 | 昆明中药厂有限公司 | Quality test method of Dianxianning tablets |
-
2015
- 2015-06-25 CN CN201510354410.0A patent/CN105194146B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1084756A (en) * | 1993-04-19 | 1994-04-06 | 高为人 | Epilepsy medicine (Dianxianning) and manufacture method thereof |
| CN1134298A (en) * | 1996-01-05 | 1996-10-30 | 谢志庆 | "Dianxianningxiwan" pills-Chinese patent medicine for epilepsy |
| CN101732515A (en) * | 2010-01-26 | 2010-06-16 | 昆明中药厂有限公司 | Quality test method of Dianxianning tablets |
Non-Patent Citations (2)
| Title |
|---|
| 于肯明，等。: ""癫痫宁胶囊的药理及毒性研究"", 《中医药研究》 * |
| 甄瑾等: "癫痫宁片治疗癫痫的随机双盲临床研究", 《内蒙古医学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816701A (en) * | 2016-03-30 | 2016-08-03 | 聂靖炜 | Brain-nourishing and refreshing capsules for treating epilepsy and dementia |
| CN107519323A (en) * | 2017-04-25 | 2017-12-29 | 兰州大学 | Rhizoma valerianae latifoliae extract is preparing the application in activating HSP70 medicines |
| CN109512813A (en) * | 2018-07-24 | 2019-03-26 | 宁夏医科大学 | Purposes of the valeric aldehyde in preparation prevention and treatment epileptic attack and cerebral injury drug |
| CN109512813B (en) * | 2018-07-24 | 2021-04-06 | 宁夏医科大学 | Application of valeraldehyde in preparing medicine for preventing and treating brain injury induced by epilepsy |
| CN109223924A (en) * | 2018-11-10 | 2019-01-18 | 兰州大学 | Epilepsy medicine (Dianxianning) adjusts the application in beta-amyloid protein drug in preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105194146B (en) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Munhoz et al. | Non-motor signs in Parkinson’s disease: a review | |
| CN105194146A (en) | Application of Dianxianning to preparation of medicine preventing and treating Alzheimer's disease | |
| Okamoto et al. | Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions | |
| Forloni | Alpha synuclein: neurodegeneration and inflammation | |
| CN105311279A (en) | Application of traditional Chinese medicine composition to preparation of medicines for preventing or treating Alzheimer's disease | |
| Yang et al. | Shenqi Xingnao Granules ameliorates cognitive impairments and Alzheimer’s disease-like pathologies in APP/PS1 mouse model | |
| Rahman et al. | Exploring the recent trends in management of dementia and frailty: focus on diagnosis and treatment | |
| Su et al. | Chronic developmental exposure to low-dose ([C8mim][PF6]) induces neurotoxicity and behavioural abnormalities in rats | |
| US10226500B2 (en) | Use of the Chinese medicine composition and Dianxianning in the preparation of a medicament for preventing or treating Alzheimer's diseases | |
| CN102784160B (en) | Application of forsythin to preparation of medicine for improving cognitive function and treating Alzheimer's diseases | |
| CN103735761B (en) | A kind of pharmaceutical composition preventing and treating Alzheimer disease and preparation method thereof | |
| Wang et al. | An integrated study of Shenling Baizhu San against hyperuricemia: efficacy evaluation, core target identification and active component discovery | |
| Samad et al. | Haloperidol-induced extra pyramidal symptoms attenuated by imipramine in rats | |
| CN105147964B (en) | A kind of Chinese medicine composition for the treatment of Alzheimer's disease containing rose and its application | |
| CN109498703B (en) | Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease | |
| CN109453159B (en) | Application of valeriana jatamansi jones extract monomer compound in preparation of anti-AD drugs | |
| CN105521076B (en) | A kind of Chinese medicine composition for the treatment of Alzheimer's disease containing rose and application | |
| JP6510017B1 (en) | Neural cell death inhibitor and food composition for neural cell death suppression | |
| CN105477008B (en) | Application of the rose polysaccharide in the medicine for preparing treatment Alzheimer's disease | |
| CN109293621A (en) | A kind of Rhizoma valerianae latifoliae extract monomeric compound and its application in treatment Alzheimer disease drug | |
| CN105920008B (en) | A kind of new application of Gastrodin aglycone derivative | |
| CN105521075B (en) | A kind of Rosa Damascana for treating Alzheimer's disease and its application | |
| CN106563061A (en) | Yuye decoction (traditional Chinese medicine decoction) composition for treating Alzheimer's disease | |
| CN105521269B (en) | A kind of rose composition for treating Alzheimer's disease and its application | |
| WO2015196402A1 (en) | Use of traditional chinese medicine composition in preparing medicines for prevention or treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |